Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Fox

Showing results (171-180 of 187) with videos related to

Pageof 19
Sort By:
Blood|November 14, 1997
Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humansC G Begley, R Basser, R Mansfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma GroupI A Cooper, M M Wolf, T I Robertson, et al.
Free Radical Biology & Medicine|March 1, 1995
Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicityL I Gordon, S G Brown, M S Tallman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.
Lancet (London, England)|November 9, 1996
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Journal of Surgical Oncology|August 1, 1983
Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapyR R Reddel, J F Thompson, D Raghavan, et al.
Lancet (London, England)|March 22, 1986
Classification of human tumours by high-resolution magnetic resonance spectroscopyC E Mountford, J K Saunders, G L May, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancerK Clarke, R L Basser, D Maher, et al.
Cancer Treatment Reports|July 1, 1984
Mitolactol chemotherapy for malignant melanoma: a phase II studyL T Malden, A S Coates, G W Milton, et al.
Bone Marrow Transplantation|July 20, 2006
Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilizationP Fu, R K Bagai, H Meyerson, et al.
Pageof 19

Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
Blood|November 14, 1997
Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humansC G Begley, R Basser, R Mansfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma GroupI A Cooper, M M Wolf, T I Robertson, et al.
Free Radical Biology & Medicine|March 1, 1995
Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicityL I Gordon, S G Brown, M S Tallman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.
Lancet (London, England)|November 9, 1996
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Journal of Surgical Oncology|August 1, 1983
Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapyR R Reddel, J F Thompson, D Raghavan, et al.
Lancet (London, England)|March 22, 1986
Classification of human tumours by high-resolution magnetic resonance spectroscopyC E Mountford, J K Saunders, G L May, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancerK Clarke, R L Basser, D Maher, et al.
Cancer Treatment Reports|July 1, 1984
Mitolactol chemotherapy for malignant melanoma: a phase II studyL T Malden, A S Coates, G W Milton, et al.
Bone Marrow Transplantation|July 20, 2006
Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilizationP Fu, R K Bagai, H Meyerson, et al.
Pageof 19